Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2019
Physicians’ perspectives on FDA approval standards and off-label drug marketing
22 January 2019 - Recently, two fundamental aspects of the US FDA’s pharmaceutical market oversight have become controversial. ...
Posted by Michael Wonder on 16 Dec 2018
2019 oncology drugs in pipeline — survey
14 December 2018 - pCODR is again undertaking its periodic survey to facilitate consistent and systematic data collection from participating ...
Posted by Michael Wonder on 27 Sep 2018
Differentiation of health-related quality of life outcomes between five disease areas: results from an international survey of patients
25 September 2018 - Health-related quality of life data generated by generic, preference-based instruments are highly demanded in health policy decision ...
Posted by Michael Wonder on 24 Jul 2018
Majority think Trump's drug plan won't lower prices they pay
23 July 2018 - A majority of the public thinks that President Trump’s drug-pricing plan will have no impact on ...
Posted by Michael Wonder on 03 Jul 2018
Deloitte survey finds biopharma companies are accelerating adoption of real-world evidence
28 June 2018 - A recent survey shows that 90% of biopharma companies are making significant investments in real-world evidence ...
Posted by Michael Wonder on 02 Jun 2018
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience
31 May 2018 - Innovative pricing agreements for medicines have been used in European markets for more than 20 years, ...
Posted by Michael Wonder on 28 Jan 2018
Is “end of life” a special case? Connecting Q with survey methods to measure societal support for views on the value of life-extending treatments
19 January 2018 - Preference elicitation studies reporting societal views on the relative value of end-of-life treatments have produced equivocal results. ...
Posted by Michael Wonder on 23 Jan 2018
EMA surveys pharma companies on their preparedness for Brexit
23 January 2018 - Planning of regulatory steps needed to ensure medicines remain on EU market. ...
Posted by Michael Wonder on 23 Sep 2017
Costly drugs to weigh on U.S. employers' expenses in 2018: survey
18 September 2017 - U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs ...
Posted by Michael Wonder on 11 May 2017
EMA launches second communication perception survey
11 May 2017 - The EMA has launched its bi-annual communication perception surveyExternal link icon. ...
Posted by Michael Wonder on 02 May 2017
Survey shows biotech industry buoyant, but fearing imminent policy change
2 May 2017 - AusBiotech’s annual survey of biotechnology industry CEOs shows the strongest year on record, but the result ...
Posted by Michael Wonder on 01 May 2017
Majorities of Democrats, Republicans and Independents support actions to lower drug costs, including allowing Americans to buy drugs from Canada
1 May 2017 - Most say importing Canadian drugs would lower costs without affecting quality, though some have concerns about unsafe ...
Posted by Michael Wonder on 02 Apr 2017
Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia
1 April 2017 - Institutional payers for pharmaceuticals worldwide appear to be increasingly negotiating confidential discounts off of the official list ...
Posted by Michael Wonder on 23 Nov 2016
AusPAR user survey results
23 November 2016 - The survey was to help the TGA identify the audience for AusPARs, understand what AusPARs were being ...
Posted by Michael Wonder on 15 Nov 2016
Pharmaceutical companies' strategies for reaching the poor are maturing but expansion is gradual
14 November 2016 - Pharmaceutical companies are getting more sophisticated in the way they get products to poor people and are ...